AstraZeneca’s supplemental New Drug Application, or sNDA, for Tagrisso in combination with chemotherapy has been accepted and granted Priority Review in the U.S. for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, or NSCLC, the company announced.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- AstraZeneca call volume above normal and directionally bullish
- Genmab price target raised to $46 from $44 at BTIG
- Fusion Pharmaceuticals and AstraZeneca’s FPI-2068 shows anti-tumor efficacy
- AstraZeneca announces first data from four pivotal Phase III trials at ESMO
- Ionis announces new results from analysis of exploratory cardiac endpoints